JP2009509171A - 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 - Google Patents

個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 Download PDF

Info

Publication number
JP2009509171A
JP2009509171A JP2008532365A JP2008532365A JP2009509171A JP 2009509171 A JP2009509171 A JP 2009509171A JP 2008532365 A JP2008532365 A JP 2008532365A JP 2008532365 A JP2008532365 A JP 2008532365A JP 2009509171 A JP2009509171 A JP 2009509171A
Authority
JP
Japan
Prior art keywords
drug
cancer
tumor
cells
dri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008532365A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009509171A5 (https=
Inventor
ポール オー．ピー． ソー，
スティーブン レスコ，
Original Assignee
シーシーシー ダイアグノスティックス， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーシーシー ダイアグノスティックス， エルエルシー filed Critical シーシーシー ダイアグノスティックス， エルエルシー
Publication of JP2009509171A publication Critical patent/JP2009509171A/ja
Publication of JP2009509171A5 publication Critical patent/JP2009509171A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008532365A 2005-09-21 2006-09-21 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験 Pending JP2009509171A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71872405P 2005-09-21 2005-09-21
US77890106P 2006-03-06 2006-03-06
PCT/US2006/036749 WO2007035842A2 (en) 2005-09-21 2006-09-21 Comprehensive diagnostic testing procedures for personalized anticancer chemotherapy (pac)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012108724A Division JP2012177706A (ja) 2005-09-21 2012-05-10 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験

Publications (2)

Publication Number Publication Date
JP2009509171A true JP2009509171A (ja) 2009-03-05
JP2009509171A5 JP2009509171A5 (https=) 2009-11-05

Family

ID=37889517

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008532365A Pending JP2009509171A (ja) 2005-09-21 2006-09-21 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
JP2012108724A Pending JP2012177706A (ja) 2005-09-21 2012-05-10 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012108724A Pending JP2012177706A (ja) 2005-09-21 2012-05-10 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験

Country Status (6)

Country Link
US (1) US20070071762A1 (https=)
EP (1) EP1946114A4 (https=)
JP (2) JP2009509171A (https=)
KR (1) KR20080066663A (https=)
CA (1) CA2623445A1 (https=)
WO (1) WO2007035842A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
JP2013533486A (ja) * 2010-07-07 2013-08-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 乳がんの診断および治療
JPWO2016117466A1 (ja) * 2015-01-22 2017-11-02 コニカミノルタ株式会社 生体物質定量方法、病理診断支援システム及びプログラム

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2359689B1 (en) * 2002-09-27 2015-08-26 The General Hospital Corporation Microfluidic device for cell separation and use thereof
US8921102B2 (en) * 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US20080090239A1 (en) * 2006-06-14 2008-04-17 Daniel Shoemaker Rare cell analysis using sample splitting and dna tags
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
EP2235536A4 (en) * 2007-12-20 2011-05-04 Lab Corp America Holdings HER-2-DIAGNOSTIC PROCEDURE
SG192544A1 (en) * 2008-01-31 2013-08-30 Univ Keio Marker for determination of sensitivity to anti-cancer agent
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
CA3069082C (en) 2008-09-20 2022-03-22 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive diagnosis of fetal aneuploidy by sequencing
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
DE102009047146B4 (de) 2009-11-25 2012-07-19 Ulrich Pachmann Verfahren zum Vorhersagen des Ansprechens einer Tumorerkrankung auf eine therapeutische Maßnahme
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
EP2726870B1 (en) 2011-06-29 2018-10-03 Academia Sinica The capture, purification and release of biological substance using a surface coating
CN102409087B (zh) * 2011-08-11 2014-01-01 厦门艾德生物医药科技有限公司 一种用于测定β-微管蛋白III 基因表达的引物、探针及检测试剂盒
KR101327533B1 (ko) 2012-12-11 2013-11-08 사회복지법인 삼성생명공익재단 환자 맞춤형 항암제 선별용 시스템
WO2014194289A1 (en) * 2013-05-31 2014-12-04 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with dna-damaging chemotherapeutic agents
TW201623605A (zh) 2014-04-01 2016-07-01 中央研究院 用於癌症診斷及預後之方法及系統
US10112198B2 (en) 2014-08-26 2018-10-30 Academia Sinica Collector architecture layout design
US12106213B2 (en) 2016-02-01 2024-10-01 Mitchell International, Inc. Systems and methods for automatically determining adjacent panel dependencies during damage appraisal
US12190358B2 (en) 2016-02-01 2025-01-07 Mitchell International, Inc. Systems and methods for automatically determining associations between damaged parts and repair estimate information during damage appraisal
US10107726B2 (en) 2016-03-16 2018-10-23 Cellmax, Ltd. Collection of suspended cells using a transferable membrane
WO2019191280A1 (en) * 2018-03-27 2019-10-03 Laboratory Corporation Of America Holdings Sandwich elisa for identifying subjects who may benefit from treatment with therapeutic agents
CN112082976A (zh) * 2019-06-14 2020-12-15 天津方得生物科技有限公司 基于药物探针及组织切片的体外药物敏感性检测方法
CN111458514A (zh) * 2019-12-18 2020-07-28 王�琦 一种外周血中的肿瘤细胞株数量的检测方法
CN111458515A (zh) * 2019-12-18 2020-07-28 王�琦 一种外周血中的肺小细胞肿瘤细胞数量的检测方法
JP7806660B2 (ja) * 2022-11-11 2026-01-27 コニカミノルタ株式会社 検出方法
PL444462A1 (pl) * 2023-04-18 2024-10-21 Uniwersytet Medyczny W Białymstoku Sposób oceny chemiowrażliwości komórek nowotworowych in vitro na leki przeciwnowotworowe i sposób diagnostyki ex vivo nowotworu piersi

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156854A1 (en) * 2002-12-06 2004-08-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US20050123977A1 (en) * 2003-12-04 2005-06-09 Ludwig Institute For Cancer Research Assay and treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744095B2 (en) * 1997-03-27 2002-02-14 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
EP1283904A2 (en) * 1999-11-03 2003-02-19 Oncotech, Inc. Cancer diagnosis using cell-sorting and gene-expression-profiles
EP1286671B1 (en) * 2000-05-15 2006-04-05 Celgene Corporation Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan
DE10043591A1 (de) * 2000-09-01 2002-03-14 Max Delbrueck Centrum Verfahren zur Erfassung von Resistenz-Profilen von Geweben und Zellinien
ES2374311T3 (es) * 2002-03-13 2012-02-15 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados.
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
WO2004052184A2 (en) * 2002-12-12 2004-06-24 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
EP1649052A1 (en) * 2003-08-01 2006-04-26 The University Of Western Australia Methods and kits for predicting the likelihood of successful treatment of cancer
WO2006055676A2 (en) * 2004-11-16 2006-05-26 The Uab Research Foundation Molecular basis for the identification of chemotherapy resistance in human tumors and the treatment thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040156854A1 (en) * 2002-12-06 2004-08-12 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
US20050123977A1 (en) * 2003-12-04 2005-06-09 Ludwig Institute For Cancer Research Assay and treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6011019894; ＴＡＮＩＭＯＴＯ，Ｋ．　ｅｔ　ａｌ．: 'ＴＯＷＡＲＤＳ　ＭＯＬＥＣＵＬＡＲ　ＭＥＤＩＣＩＮＥ：　ＣＡＮＣＥＲ　ＰＨＡＲＭＡＣＯＧＥＮＯＭＩＣＳ，　ＰＥＲＳＯＮＡＬＩＺＥＤ　ＭＥＤＩＣＩＮＥ，　ＡＮＤ　ＯＵＲ　ＲＥＣＥＮＴ　ＡＰＰＲＯＡＣＨＥ' Ａｎｎ．Ｃａｎｃｅｒ　Ｒｅｓ．Ｔｈｅｒ． Ｖｏｌ．１１　Ｎｏ．１／２, 2003, Ｐａｇｅ．６１-６４，６４（１），６４（２），６５-７２ *
JPN6012000258; 冨田俊樹　他: '頭頚部原発Ｉ・ＩＩ期非ホジキンリンパ腫の臨床統計学的検討　予後因子の解析および治療法の評価' 日本耳鼻咽喉科学会会報 Ｖｏｌ．１０２　Ｎｏ．６, 1999, Ｐａｇｅ．８０９-８１７ *
JPN6012000259; 清家和裕，　宮崎勝: '消化器外科学　大腸癌術後補助免疫化学療法-臨床成績およびその個別化' 週刊医学のあゆみ Ｖｏｌ．２０７　Ｎｏ．６, 2003, Ｐａｇｅ．４４１-４４２ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013533486A (ja) * 2010-07-07 2013-08-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 乳がんの診断および治療
WO2012133047A1 (ja) * 2011-03-25 2012-10-04 コニカミノルタエムジー株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
JPWO2012133047A1 (ja) * 2011-03-25 2014-07-28 コニカミノルタ株式会社 免疫組織染色法、およびこれを用いた抗体医薬の有効性を判定する方法
JPWO2016117466A1 (ja) * 2015-01-22 2017-11-02 コニカミノルタ株式会社 生体物質定量方法、病理診断支援システム及びプログラム
US10746740B2 (en) 2015-01-22 2020-08-18 Konica Minolta, Inc. Biological substance quantitation method, pathological diagnosis support system, and recording medium storing computer readable program

Also Published As

Publication number Publication date
CA2623445A1 (en) 2007-03-29
EP1946114A2 (en) 2008-07-23
US20070071762A1 (en) 2007-03-29
EP1946114A4 (en) 2010-05-26
WO2007035842A3 (en) 2007-09-20
WO2007035842A2 (en) 2007-03-29
KR20080066663A (ko) 2008-07-16
JP2012177706A (ja) 2012-09-13

Similar Documents

Publication Publication Date Title
JP2012177706A (ja) 個別化抗癌化学療法（ｐａｃ）のための包括的な診断試験
Mebratie et al. Review of immunohistochemistry techniques: Applications, current status, and future perspectives
Kim et al. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression
JP5048757B2 (ja) 診断指標または予測指標としての細胞内局在プロフィールの使用
JP6259828B2 (ja) 未分化リンパ腫キナーゼ（ａｌｋ）をマーカーとして使用する治療応答性非小細胞肺癌の同定法
Nitta et al. New methods for ALK status diagnosis in non–small-Cell lung Cancer: an improved ALK immunohistochemical assay and a new, Brightfield, dual ALK IHC–In situ hybridization assay
Portier et al. HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma
Wu et al. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement
JP6626097B2 (ja) 乳がんにおける腫瘍内ｈｅｒ２不均質性の意義及びそのための使用
Zhu et al. Six stroma-based RNA markers diagnostic for prostate cancer in European-Americans validated at the RNA and protein levels in patients in China
Mertens et al. Comparative expression of trophoblast cell-surface antigen 2 (TROP2) in the different molecular subtypes of invasive breast carcinoma: An immunohistochemical study of 94 therapy-naive primary breast tumors
Pierceall et al. Strategies for H‐score normalization of preanalytical technical variables with potential utility to immunohistochemical‐based biomarker quantitation in therapeutic reponse diagnostics
CA2694409A1 (en) Method for predicting response to tamoxifen
Kato et al. Evaluation of HER2 gene amplification in invasive breast cancer using a dual‐color chromogenic in situ hybridization (dual CISH)
Jia et al. Identification of prognosis-related proteins in advanced gastric cancer by mass spectrometry-based comparative proteomics
US20070031902A1 (en) Predictive Methods For Cancer Chemotherapy
JP2018535432A (ja) 転移性去勢抵抗性前立腺癌（ｍＣＲＰＣ）患者における治療選択のためのバイオマーカーとしてのアンドロゲン受容体バリアント７
US20140142101A1 (en) Correlation of molecular markers with clinical outcome in gbm patients radiation treated with or without gefitinib
KR102518761B1 (ko) 췌장암의 예후 예측 방법 및 이를 위한 키트
Giltnane et al. AQUA and FISH analysis of HER‐2/neu expression and amplification in a small cell lung carcinoma tissue microarray
Tsiambas et al. Evaluation of epidermal growth factor receptor gene and chromosome 7 alterations in squamous cell carcinoma of the larynx, using chromogenic in situ hybridization on tissue microarrays
CN115552248A (zh) 用于评价肿瘤样品中egfr和egfr配体表达的组织化学系统和方法
RU2846787C1 (ru) Способ выявления циркулирующих клеток в крови больных раком легкого с помощью проточной цитометрии с использованием опухолеспецифичных ДНК-аптамеров
WO2010017331A1 (en) Signal pathway alterations and drug target elevations in primary metachronous metastatic colorectal cancer compared to non-metastatic disease
Momota et al. Detection of Her 2/Neu Equivocal Immunochemistry by Fish in Breast Carcinoma–A Study from Single Tertiary Care Hospital

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110421

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120731

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20120928

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130612

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130813

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140325

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140403

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140501

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140523

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140528